A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation

Journal of Interventional Cardiac Electrophysiology

Volumn 41, Issue 3, 2014, Pages 231-236

  Snipelisky, David ^a   Ray, Jordan C ^a   Ung, Ryan ^a   Duart, Melissa ^a   Kauffman, Christine ^b   Kusumoto, Fred ^b  

^a MAYO CLINIC   (United States)

^b Division of Cardiovascular Medicine   (United States)

Author keywords

Bleeding risk; Cryoablation; Novel anticoagulants; Radiofrequency ablation

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN; HEPARIN; PROTAMINE SULFATE; RIVAROXABAN; WARFARIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ABLATION THERAPY; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD; BLOOD CLOTTING TIME; CRYOABLATION; ECCHYMOSIS; ECHOCARDIOGRAPHY; FEMALE; FEMORAL ARTERY; HEART ATRIUM FIBRILLATION; HEMATOMA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERICARDIAL EFFUSION; RADIOFREQUENCY ABLATION; THROMBOEMBOLISM; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; CATHETER ABLATION; CHEMICALLY INDUCED; COMORBIDITY; COMPLICATION; CRYOSURGERY; RETROSPECTIVE STUDY; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CATHETER ABLATION; COMORBIDITY; CRYOSURGERY; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MORPHOLINES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE; THIOPHENES; TREATMENT OUTCOME; WARFARIN;

EID: 84916202320     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-014-9948-1     Document Type: Article

References (14)

1. Packer, D. L., Kowal, R. C., Wheelan, K. R., et al. (2013). Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. Journal of the American College of Cardiology, 61(16), 1713–1723.
2. Tse, H. F., Reek, S., Timmermans, C., et al. (2013). Pulmonary vein isolation using transvenous catheter cryoablation for treatment of atrial fibrillation without risk of pulmonary vein stenosis. Journal of the American College of Cardiology, 42(4), 752–758.
3. Tayebjee, M. H., Hunter, R. J., Baker, V., et al. (2011). Pulmonary vein isolation with radiofrequency ablation followed by cryotherapy: a novel strategy to improve clinical outcomes following catheter ablation of paroxysmal atrial fibrillation. Europace, 13(9), 1250–1255.
4. Mansour, M., Forleo, G. B., Pappalardo, A., et al. (2010). Combined use of cryoballoon and focal open-irrigation radiofrequency ablation for treatment of persistent atrial fibrillation: results from a pilot study. Heart Rhythm, 7(4), 452–458.
5. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine, 361(12), 1139–1151.
6. Patel, M. R., Mahaffey, K. W., Garg, J., et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine, 365(10), 883–891.
7. Snipelisky, D., Kauffman, C., Prussak, K., Johns, G., Venkatachalam, K., & Kusumoto, F. (2012). A comparison of bleeding complications post-ablation between warfarin and dabigatran. Journal of Interventional Cardiac Electrophysiology, 35(1), 29–33.
8. Lakkireddy, D., Reddy, Y. M., Di Biase, L., Vanga, S. R., et al. (2012). Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. Journal American College of Cardiology, 59(13), 1168–1174.
9. Winkle, R. A., Mead, R. H., Engel, G., Kong, M. H., & Patrawala, R. A. (2012). The use of dabigatran immediately after atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 23(3), 264–268.
10. Eitel, C., Koch, J., Sommer, P., et al. (2013). Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace, 15(11), 1587–1593.
11. Snipelisky, D., & Kusumoto, F. (2013). Current strategies to minimize the bleeding risk of warfarin. Journal of Blood Medicine, 4, 89–99.
12. Spinler, S. A., & Shafir, V. (2012). New oral anticoagulants for atrial fibrillation. Circulation, 126(1), 133–137.
13. Knight, B. P. (2012). Anticoagulation for atrial fibrillation: what is the optimal strategy? Journal of the American College of Cardiology, 59(13), 1175–1177.
14. Baglin, T. (2013). Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban. British Journal of Haematology, 163(2), 160–167.